Development of diagnostic and prognostic tests for malignancies based on autoantibody detection
Project is carried out within the European Regional Development Fund (ERDF) 220.127.116.11. activity "Support for Science and Research”.
Project identification # 2010/0231/2DP/18.104.22.168.0/10/APIA/VIAA/044
Project activity period: 36 months (2011.01.03. – 2013.12.31.)
Project funds: 367 428 LVL
Scientific manager: Dr. biol.Aija Linē
The overall aim of the project is to apply advanced molecular biology technologies for the development and validation of conceptually novel, non-invasive serological test for the early detection of cancer and prediction the course of disease, thus facilitating the integration of science and industry and contributing to the improvement of community healthcare and the development of economy.
The specific aim of the project is to identify autoantibody biomarker sets relevant for diagnosis and/or prognosis of gastric and prostate cancer and to use them for the development of prototypes of multiplex serological tests, and to evaluate the technical and diagnostic performance of these tests.
The study carried out within the project is interdisciplinary and comprises branches of biological, medical and computer sciences, and corresponds to the priority science area defined by the subparagraph 4.2.4. of the Regulations of Cabinet of Ministers (RCM) No. 752 – community health.
The project complies with the criteria of a project that is not linked to commercial activity, because it is realized by a scientific institution, the intellectual property rights that result from the basic activities of the scientific institutions are transferred to public possession and public availability of the results of the project will be ensured, which fits to the definition in the subparagraph 3.1.1. of the RCM No. 752.
In order to achieve the aims of the project, following activities will be performed:
1.1. Industrial research aimed to identify a unique combination of tumour antigens capable to detect the presence of serum autoantibodies as diagnostic/prognostic biomarkers and to assess their diagnostic significance. Objectives:
1.1.1. Establishment of serum sample and clinical information biobank;
1.1.2. Development of a diagnostic biomarker set for gastric cancer;
1.1.3. Development of a diagnostic and/or prognostic biomarker set for prostate cancer.
1.2. Experimental development aimed at the elucidation of the most appropriate technological solution for the development of clinically relevant multiplex assay for the detection of autoantibody biomarkers, production of test prototypes and assessment of the technical and diagnostic performance. Objectives:
1.2.1. Evaluation of the suitability of the recombinant protein microarray and Luminex xMAP microsphere-
based technologies for the production of a multiplex serological assay;
1.2.2. Production of prototype and testing to determine the sensitivity and specificity of the test.
2. Dissemination of project results.
3. Protection of intellectual/ industrial property rights derived from the research project.
The project will be carried out at the Latvian Biomedical Research and Study Centre in a period of 36 months starting from the 1st of January 2011. The total eligible costs of the project are 367 428 LVL, including requested ERDF contribution of 339870 LVL.